Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 18 November 2021, 14:28 HKT/SGT
Share:
    

Source: Eisai
Eisai Receives the 'Most Liked!' IR Award at The 2021 IR Award

TOKYO, Nov 18, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that it has been selected as the winner of the "Most Liked!" IR Award at the 2021 IR Award, hosted by the Japan Investor Relations Association.


The "Most Liked!" IR Award has been newly created for commemorating the 25th anniversary of the Best IR Award in 2020. The award is designed to reflect the viewpoints of companies that applied for the IR Award based on their voting, share their proactive IR experiences, and realize best practices. The theme for 2021 is "IR activities contributing sustainability," awarding companies that have actively promoted information disclosure and their dialogue with investors on sustainability-related matters. Of the companies that applied for the 2021 IR Award, 178 companies entered the 'Most Liked!" IR Award and the top 17 companies, including Eisai, were selected based on a mutual vote by the candidate companies.

For further details, please visit the JIRA website: https://www.jira.or.jp/english/.

Eisai has focused on disseminating information regarding financial capital and non-financial capital value relevance that link to corporate value for longer-term as well as continuously through publicizing the results of the analysis of the correlation between ESG-related indicators and PBR (Price Book-value Ratio) , holding discussion meetings with investors, or publishing the Eisai Value Creation Report. The award was given to Eisai with "empathy" for Eisai's efforts to visualize ESG.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Together with strengthening its ESG initiatives in order to realize this corporate philosophy, Eisai respects the rights of shareholders and investors, ensures fairness and transparency in management, and works on its IR activities to aid the enhancement of corporate value.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 18, 2024 09:53 HKT/SGT
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 17, 2024 15:17 HKT/SGT
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 3, 2024 15:24 HKT/SGT
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Apr 1, 2024 08:39 HKT/SGT
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Mar 29, 2024 14:51 HKT/SGT
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Mar 29, 2024 14:19 HKT/SGT
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
Mar 29, 2024 13:32 HKT/SGT
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
Mar 21, 2024 16:36 HKT/SGT
Lifenet and Eisai Co-Develop Dementia Insurance "be"
Mar 21, 2024 15:10 HKT/SGT
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 6, 2024 16:47 HKT/SGT
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: